CA
NZ
UK
AU
IND
US
OmniAb (NASDAQ:OABI) was among the heavier decliners in the Russell 2000 on Tuesday, October 6, tumbling to about $4.44. No company announcement explaining the move was found, and noEarningsrelease, financing or trial readout tied to the session turned up in the sources reviewed.
Pacific Biosciences (NASDAQ:PACB), known as PacBio, soared on Tuesday, October 6, trading around $3.36. The move put it among the standout gainers in the Russell 2000. The jump was tied to a collaboration with TychoBio focused on RNA data. Financial terms and further details …
Vaxcyte (NASDAQ:PCVX) slipped in premarket trading on Tuesday, October 6, to around $71.04, after the vaccine developer launched a combined $1 billion capital raise. The offering consists of $500 million of common stock and pre-funded warrants plus $500 million of convertible notes due 2032.
Prime Medicine (NASDAQ:PRME) jumped on Tuesday, October 6, trading around $3.71, which placed it among the day's notable gainers. No catalyst was given, and no company announcement explaining the move was found.
Personalis (NASDAQ:PSNL) drew attention on Tuesday, October 6, after BTIG downgraded the genomics company to Neutral from Buy. A downgrade of this kind means the analyst no longer sees enough upside to recommend buying the shares, but is not calling for investors to sell. …
Qiagen (NYSE:QGEN) was in focus in theRussell 1000on Tuesday, October 6, after Barclays upgraded the diagnostics and research-tools company to Overweight from Equal Weight. The stock's move on the day was not captured in available market reports, and the price target was not available.
Rezolute (NASDAQ:RZLT) drew attention on Tuesday, October 6, after Cantor Fitzgerald upgraded the biotech company to Overweight from Neutral. The change means Cantor now expects the shares to do better than the stocks it compares them with, rather than simply track them. How the …
GeneDx (NASDAQ:WGS) fell on Tuesday, October 6, trading around $71.60. No company-specific news was found to explain the decline. The stock moved lower alongside other diagnostics and genetic-testing companies as health care lagged the rest of the market.
● IO Biotech filed under Chapter 7 of the USBankruptcyCode in the District of Delaware on 31 March 2026 and ceased operations; the trailing Q flags an issuer in bankruptcy.
● Lipella filed for Chapter 11 protection on 30 March 2026 in the U.S.BankruptcyCourt for the Western District of Pennsylvania.
Please wait processing your request...